| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | AKR7A3 |
| Uniprot No | O95154 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-331aa |
| 氨基酸序列 | MSRQLSRARPATVLGAMEMGRRMDAPTSAAVTRAFLERGHTEIDTAFVYSEGQSETILGGLGLRLGGSDCRVKIDTKAIPLFGNSLKPDSLRFQLETSLKRLQCPRVDLFYLHMPDHSTPVEETLRACHQLHQEGKFVELGLSNYAAWEVAEICTLCKSNGWILPTVYQGMYNAITRQVETELFPCLRHFGLRFYAFNPLAGGLLTGKYKYEDKDGKQPVGRFFGNTWAEMYRNRYWKEHHFEGIALVEKALQAAYGASAPSMTSATLRWMYHHSQLQGAHGDAVILGMSSLEQLEQNLAAAEEGPLEPAVVDAFNQAWHLVAHECPNYFR |
| 预测分子量 | 64.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于AKR7A3重组蛋白的3篇参考文献摘要信息：
1. **文献名称**：*"Cloning, expression, and characterization of human AKR7A3: a monomeric aldo-keto reductase with substrate specificity for carbonyl compounds"*
**作者**：Barski OA, et al.
**摘要**：该研究成功克隆并在大肠杆菌中表达了人源AKR7A3重组蛋白，证实其属于单体醛酮还原酶家族，对多种羰基化合物(如4-羟基壬烯醛)具有催化活性，提示其在氧化应激相关的解毒功能中的作用。
2. **文献名称**：*"Structural insights into the substrate specificity of AKR7A3 through crystallographic analysis"*
**作者**：Liu Y, et al.
**摘要**：通过X射线晶体学解析了AKR7A3重组蛋白的三维结构，揭示了其底物结合口袋的关键氨基酸残基，阐明了其对特定羰基底物的选择性机制，为设计靶向抑制剂提供结构基础。
3. **文献名称**：*"AKR7A3 protects against oxidative stress by regulating Nrf2 signaling in cellular models"*
**作者**：Penning TM, et al.
**摘要**：研究通过重组AKR7A3蛋白的功能实验，证明其通过代谢脂质过氧化产物激活Nrf2抗氧化通路，减轻细胞氧化损伤，提示其在神经退行性疾病中的潜在保护作用。
4. **文献名称**：*"Functional characterization of AKR7A3 variants in metabolic disorders using recombinant protein assays"*
**作者**：Jin Y, et al.
**摘要**：通过体外重组AKR7A3蛋白活性分析，评估了多个单核苷酸多态性(SNPs)对其酶活性的影响，发现特定突变与代谢疾病风险相关，为个体化治疗提供依据。
注：以上为基于领域内典型研究的概括性示例，实际文献需通过PubMed或Web of Science等数据库检索具体文章。
**Background of AKR7A3 Recombinant Protein**
AKR7A3 (aldo-keto reductase family 7 member A3) is a member of the aldo-keto reductase (AKR) superfamily, a group of NADPH-dependent enzymes involved in detoxification, steroid metabolism, and biosynthesis. Specifically, AKR7A3 is categorized within the AKR7 subfamily, which is implicated in the reduction of toxic aldehydes generated during oxidative stress or xenobiotic metabolism. This cytosolic enzyme plays a protective role in cellular defense mechanisms by converting reactive aldehydes, such as lipid peroxidation-derived 4-hydroxynonenal (4-HNE), into less reactive alcohols, thereby mitigating oxidative damage.
Structurally, AKR7A3 adopts the conserved (α/β)8-barrel fold characteristic of AKR enzymes, with a catalytic tetrad (Tyr, Lys, Asp, His) essential for substrate binding and cofactor interaction. Its substrate specificity and catalytic efficiency are influenced by unique loop regions near the active site.
Recombinant AKR7A3 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells*)*, enabling studies on its enzymatic activity, substrate preferences, and regulatory mechanisms. Research highlights its potential relevance in diseases linked to oxidative stress, including neurodegenerative disorders (e.g., Alzheimer’s), cancer, and metabolic syndromes. Additionally, AKR7A3 is studied for its role in drug metabolism, particularly in the bioactivation or inactivation of therapeutic agents and environmental toxins.
The availability of recombinant AKR7A3 facilitates drug discovery efforts, serving as a tool for screening inhibitors or modulators that could enhance cellular detoxification pathways. Ongoing studies aim to elucidate its tissue-specific functions and therapeutic potential in oxidative stress-related pathologies.
×
